These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34922745)

  • 1. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence.
    Chaudhari VA; Mitra A; Gupta V; Ostwal V; Ramaswamy A; Engineer R; Sirohi B; Shetty N; Bal M; DeSouza A; Bhandare MS; Shrikhande SV
    Surgery; 2022 May; 171(5):1388-1395. PubMed ID: 34922745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
    Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
    Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
    Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
    Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
    Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
    ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
    Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
    Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence.
    Ratnayake CBB; Roberts KJ; Pandanaboyana S
    Chin Clin Oncol; 2022 Feb; 11(1):2. PubMed ID: 35184565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.
    Yoshitomi H; Sakai N; Kagawa S; Takano S; Ueda A; Kato A; Furukawa K; Takayashiki T; Kuboki S; Miyzaki M; Ohtsuka M
    Langenbecks Arch Surg; 2019 Jun; 404(4):451-458. PubMed ID: 30868241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
    Inoue Y; Saiura A; Oba A; Ono Y; Mise Y; Ito H; Sasaki T; Ozaka M; Sasahira N; Takahashi Y
    J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):143-155. PubMed ID: 33058515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
    Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
    Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
    Sternby H; Andersson B
    Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Jung HS; Kim HS; Kang JS; Kang YH; Sohn HJ; Byun Y; Han Y; Yun WG; Cho YJ; Lee M; Kwon W; Jang JY
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer.
    Jung HS; Kwon W; Yun WG; Paik WH; Hyub Lee S; Ryu JK; Oh DY; Lee KB; Chie EK; Jang JY
    J Hepatobiliary Pancreat Sci; 2024 Oct; 31(10):737-746. PubMed ID: 39034526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
    Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
    Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
    Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
    Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.